Skip to content
Home » Glossary

Glossary

  • Abnormal cell growth
  • ADC (antibody-drug conjugate)
  • Adenosquamous carcinoma
  • Adjuvant
  • Advanced
  • Advanced breast cancer
  • Advanced HER2-positive breast cancer
  • Advanced NSCLC
  • ALK
  • ALK+
  • Anaemia
  • Anaplastic lymphoma kinase positive (ALK+)
  • Antibody-drug conjugate
  • Antigen
  • Antigens
  • Avastin
  • B cells
  • Basal cell carcinoma
  • Bone marrow
  • BRAF
  • Carcinoma
  • Chemotherapy
  • Clinical trial/study
  • CNS
  • Complete remission
  • Complete response
  • Cost Share Programme
  • CRC
  • Cytotoxic
  • DNA
  • Early HER2-positive breast cancer
  • EGFR
  • ES-SCLC
  • Extensive-stage
  • Follicular lymphoma
  • Funded treatment
  • GBM
  • HER2
  • HER2-positive breast cancer
  • Hodgkin's lymphoma
  • Immune system
  • Immunotherapy
  • Indolent
  • Induction treatment
  • Intravenous infusion
  • Large cell carcinoma
  • Lymph nodes
  • Lymph system
  • Lymphatic system
  • Lymphocyte
  • Lymphocytes
  • Maintenance therapy
  • Malignant
  • Medsafe
  • Melanoma
  • Mesothelioma
  • Metastatic
  • Metastatic NSCLC
  • Monoclonal antibodies
  • Monoclonal antibody
  • Neoadjuvant
  • Non-Hodgkin’s lymphoma
  • Non-PHARMAC funded medicines
  • Non-squamous cell carcinoma (also called adenocarcinoma)
  • NSCLC
  • OS
  • Overall Survival
  • Partial remission
  • Partial response
  • Pathological complete response (pCR)
  • Pathologist
  • PD-L1
  • PHARMAC
  • Platelets
  • Progression
  • Progression-free survival
  • Proteins
  • Radiotherapy (sometimes called ‘radiation therapy’)
  • Red blood cells
  • Refractory
  • Registration
  • Remission
  • Response rate
  • Sarcoma
  • Sarcomatoid carcinoma
  • Small-cell lung cancer (SCLC)
  • Spleen
  • Squamous cell carcinoma
  • Subcutaneous
  • Subcutaneous injection
  • Targeted therapies
  • Tissue biopsy
  • TNBC
  • Triple negative breast cancer
  • Unfunded treatment
  • Unresectable cancer
  • White blood cells
  • Roche Cost Share Programmes
  • Approval & funding of medicines in New Zealand
  • Finding a private treatment provider
  • Glossary
  • Contact Us
  • Understanding your cancer through genomic profiling
  • Roche New Zealand
  • Legal Statement
  • Privacy Statement
  • Glossary
  • Contact Us
© 2022 Roche Products (New Zealand) Limited. For more information about Roche, please visit www.roche.co.nz.  All trademarks herein are protected by law. Access to this site is subject to the terms in our Legal Statement. You accept these terms by continuing to access this site.
This site was last updated in April 2022. M-NZ-0000084-V6.0/NA11148/APR2022

You are about to leave the site to one that is not controlled or developed by Roche Products (New Zealand) Ltd.

Roche does not endorse or control, the content of any linked websites and if you click on any of those links you agree that Roche has no responsibility or duty to you for anything that happens to you as a result. If the linked site is outside New Zealand’s jurisdiction, the information may not be consistent with New Zealand’s legislation, advertising codes or the relevant New Zealand registered Data Sheet.

Please refer to the Data Sheet or Consumer Medicine Information on the Medsafe website for product information applicable to New Zealand.

Ok Continue Close